Phase 2 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Cardiovascular Disease
This is a study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in patients with hypertriglyceridemia and established cardiovascular disease (CVD).
Principal Investigator: Christie Ballantyne, M.D.
For more information, please contact:
Phone: (713) 798-8800
Terry Techmanski, RN
Phone: (713) 798-5845